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1. Introduction 
Seven transmembrane receptors (7TMRs; also designated as G-protein coupled receptors 
(GPCRs)) form the largest and evolutionarily well conserved family of cell-surface receptors, 
with more than 800 members identified in the human genome. 7TMRs are the targets both 
for a plethora of endogenous ligands (e.g. peptides, glycoproteins, lipids, amino acids, 
nucleotides, neurotransmitters, odorants, ions, and photons) and therapeutic drugs and 
transduce extracellular stimuli into intracellular responses mainly via coupling to guanine 
nucleotide binding proteins (G-proteins) (McGraw & Liggett, 2006). 
These receptors have traditionally been viewed as monomeric entities and only more recent 
biochemical and biophysical studies have changed this view. The idea that 7TMRs might 
form dimers or higher order oligomeric complexes has been formulated more than 20 years 
ago and since then intensively studied. In the last decade, bioluminescence resonance 
energy transfer (BRET) was one of the most commonly used biophysical methods to study 
7TMRs oligomerization. This technique enables monitoring physical interactions between 
protein partners in living cells fused to donor and acceptor moieties. It relies on non-
radiative transfer of energy between donor and acceptor, their intermolecular distance (10 – 
100 Å) and relative orientation. Over this period the method has progressed and several 
versions of BRET have been developed that use different substrates and/or energy 
donor/acceptor couples to improve stability and specificity of the BRET signal. This chapter 
outlines BRET-based approaches to study 7TMRs oligomerization (e.g. BRET saturation and 
competition assays), control experiments needed in the interpretation i.e. establishing 
specificity of BRET results and mathematical models applied to quantitatively assess the 
oligomerization state of studied receptors. 
2. Seven transmembrane receptors (7TMRs): Structure and characteristics 
Primary sequence comparisons reveal that 7TMRs share sequence and topology similarities 
allowing them to be classified as a super-gene family. These receptors are characterized by 
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seven hydrophobic stretches of 20-25 amino acids, predicted to form transmembrane -helices. 
Prediction of transmembrane folding was based largely on the method proposed by Kyte and 
Doolitle (Kyte & Doolittle, 1982). This method plots the hydrophobicity of the amino acids 
along the sequence, assigning each amino acids a hydrophobicity index. By summing this 
index over a window of nine residues, the transmembrane sequence is postulated when index 
reaches the value of 1.6 for a stretch of ~20 amino acids. This number is based on the 
assumption that the membrane spanning sequences of protein are -helical and that about six 
helical turns are required to span the lipid bilayer (Hucho & Tsetlin, 1996). The highly 
hydrophobic -helices that serve as transmembrane spanning domains (TMs) are connected 
by three extracellular (ECL) and three intracellular (ICL) hydrophilic loops. Amino (N)-
terminal fragment is extracellular and the carboxyl (C)-terminal tail is intracellular. In the 
recent years this common structural topology was also confirmed by three-dimensional 
crystal structure of some 7TMR members (reviewed by (Salon et al., 2011)). Additionally, 
7TMRs may undergo a variety of posttranslational modifications such as N-linked 
glycosylation, formation of disulfide bonds, palmitoylation and phosphorylation. 7TMRs 
contain at least one consensus sequence for N-linked glycosylation (Asn-x-Ser/Thr), usually 
located near the N-terminus, although there are potential glycosylation sites in the 
intracellular loops. They also contain a number of conserved extracellular cysteine residues, 
some of which appear to play a role in stabilizing the receptor's tertiary structure. An 
additional highly conserved cysteine can be present within the C-terminal tail of many 
7TMRs. When palmitoylated, it may anchor a part of cytoplasmic tail of the receptor to the 
plasma membrane, thus forming the fourth ICL and controlling the tertiary structure. 
Consensus sequences for potential phosphorylation sites (serine and threonine residues) are 
located in the second and third ICLs, and in particular, in the intracellular C-terminal tail. The 
most obvious structural differences between the receptors in subgroups are the length of their 
N-terminal fragment and the loops between TMs. Originally, 7TMRs were divided into six 
groups, A – F; families (also known as "groups" or "classes") A, B and C included all 
mammalian 7TMRs. Genome projects then generated numerous new 7TM sequences and 
more than 800 human 7TMRs were reclassified into five families, A – E (reviewed by 
(Gurevich & Gurevich, 2006; Salon et al., 2011)). 
Family A (also known as the rhodopsin family) is by far the largest family of 7TMRs 
(containing ~700 members), and includes many of the receptors for biogenic amines and 
small peptides. It is characterized by very short N- and C-termini as well as several highly 
conserved amino acids. In most cases TMs serve as the ligand-binding site. This family 
contains some of the most extensively studied 7TMRs, the opsins and the ǃ-adrenergic 
receptors. Recent structural information for a few family A 7TMR members (e.g. rhodopsin, 
opsin, human ǃ2-adrenergic receptor, turkey ǃ1-adrenergic receptor, human A2A-adenosine 
receptor, CXC chemokine receptor type 4 and D3-dopamine receptor) confirmed an obvious 
conservation of the topology and seven-transmembrane architecture (Salon et al., 2011). 
Family B (secretin-receptor family), which has considerably fewer members i.e. 15, is 
characterized by a long N-terminus (>400 amino acids) containing six conserved cysteine 
residues that contribute to three conserved disulfide bonds, which provide structural 
stability, and a conserved cleft for the docking of often helical C-terminal region of the 
peptide ligands. Natural ligands for family B 7TMRs are all moderately large peptides, such 
as calcitonin, parathyroid hormone and glucagon. Family C (metabotropic glutamate 
family) contains 15 members that are the metabotropic glutamate receptors (mGluRs), the 
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Ca2+ sensing receptor, and the receptor for the major excitatory neurotransmitter in the 
central nervous system, the Ǆ-aminobutyric acid (GABAB) receptor and orphan receptors. 
This family has a very large N-terminal domain (>600 amino acids), which bears the agonist 
binding site and also a long C-tail (Kenakin & Miller, 2010; McGraw & Liggett, 2006). 
Notably, family C members form obligatory dimers (Kniazeff et al., 2011). Two ancillary 
families consist of class D (adhesion family), containing 24 members, and class E (frizzled 
family), with 24 members. 
3. 7TMRs homo- and hetero-oligomerization 
In 1983, Fuxe et al. (Fuxe et al., 1983) formulated the hypothesis about the existence of 
homo-dimers for different types of 7TMRs and in the same year the first demonstration of 
7TMRs homo-dimers and homo-tetramers of muscarinic receptors was published (Avissar et 
al., 1983). However, the evidence for dimerization existed even before that. Following 
classical radio-ligand studies on the insulin receptor (de Meyts et al., 1973), negative 
cooperativity, for which dimerization is a prerequisite, has also been demonstrated for ǃ2-
adrenergic receptor (ǃ2-AR) (Limbird et al., 1975) and thyrotrophin-stimulating hormone 
(TSH) receptor (De Meyts, 1976) binding in the early 70’s, before they were shown to be 
7TMRs and this issue remained controversial for over two decades. 7TMRs can be either 
connected to identical partner(s), which results in formation of homo-dimers (or homo-
oligomers), or to structurally different receptor(s), which results in formation of hetero-
dimers (hetero-oligomers). 7TMR dimerization was proposed to play a potential role in i) 
receptor maturation and correct transport to the plasma membrane, ii) ligand-promoted 
regulation, iii) pharmacological diversity (e.g. positive and negative ligand binding 
cooperativity), iv) signal transduction (potentiating/attenuating signaling or changing G-
protein selectivity), and v) receptor internalization and desensitization (Terrillon & Bouvier, 
2004). The first widely accepted demonstration of 7TMR hetero-dimerization came from the 
GABAB (GBBR) receptors that exclusively function in a heteromeric form (White et al., 1998).  
There is now considerable evidence to indicate that 7TMRs can form and function as homo-
dimers and hetero-dimers (reviewed by (Filizola, 2010; Gurevich & Gurevich, 2008a; 
Palczewski, 2010))  and that these dimers may have therapeutic relevance (Casado et al., 2009). 
Hetero-dimerization in the C family of receptors has been most extensively studied and for 
some experts in the field of 7TMRs the only one demonstrated to form real dimers (for recent 
review see (Kniazeff et al., 2011)). In this family of 7TMRs receptors hetero-dimerization is 
important for either receptor function, proper expression on the cell surface or enhancing 
receptor activity. In the most numerous family A 7TMRs dimerization was extensively 
studied, although with few exceptions functional role of receptor self-association is in most 
cases unclear. Compelling evidence for the dimerization in the family A 7TMR was only 
recently  demonstrated in vivo by Huhtaniemi’s group, who was able to rescue the LH receptor 
knockout phenotype by complementation i.e. co-expressing two nonfunctional receptor 
mutants in the knockout mice (Rivero-Muller et al., 2010). Members of the family B 7TMRs 
have also only recently been shown to associate as stable homo-dimers. The structural basis of 
this, at least for the prototypic secretin receptor, is the lipid-exposed face of TM4. This complex 
has been postulated as being important for the structural stabilization of the high affinity 
complex with G-protein (reviewed by (reviewed by (Kenakin & Miller, 2010)). 
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In addition to widespread intra-family hetero-dimerization, inter-family hetero-dimerization 
has also been reported, at least between both of the family A members ǃ2-AR and opsin and 
the family B member gastric inhibitory polypeptide receptor (GIP) (Vrecl et al., 2006), and 
between the family A serotonin 5-HT2A receptors and the family C mGluR2 (Gonzalez-Maeso 
et al., 2008). Both types of hetero-dimers were demonstrated to be functional, either by their 
ability to induce cAMP production upon agonist stimulation (family A/B hetero-dimer), or by 
their ability to modulate G-protein coupling (family A/C hetero-dimer). 
3.1 Dimerization interface 
Growing experimental data support the view that 7TMRs exist and function as contact 
dimers or higher order oligomers with TM regions at the interfaces. In contact 
dimers/oligomers of 7TMRs, the original TM helical-bundle topology of each individual 
protomer is preserved and interaction interfaces are formed by lipid-exposed surfaces. 
Although domain-swap models, i.e. models in which domains TM1/TM5 and TM6/TM7 
would exchange between protomers, have also been proposed in the literature, there is 
there is limited direct evidence that supports these assumptions. On the other hand, 
compelling experimental evidence exists for the involvement of lipid exposed surfaces of 
TM1, TM4 and/or TM5 at the dimerization/oligomerization interfaces of several 7TMRs. 
Besides, the interface may depend on additional stabilizing factors such as the coiled-coil 
interactions reported in the GABAB receptor and the disulfide bridge interactions in the 
muscarinic and the other class C receptors (reviewed by (Filizola)). A web service, named 
G-protein coupled Receptors Interaction Partners (GRIP) that predicts the interfaces for 
7TMRs oligomerization is also available at http://grip.cbrc.jp/GRIP/index.html (Nemoto 
et al., 2009). G protein coupled Receptor Interaction Partners DataBase (GRIPDB) has also 
been developed, which provides information about 7TMRs oligomerization i.e. 
experimentalaly indentified 7TMRs oligomers, as well as suggested interfaces for the 
oligomerization (Nemoto et al., 2011). 
3.2 Therapeutic application and drug discovery 
7TMRs are one of the most important drug targets in the pharmaceutical industry; 
approximately 40% of the prescription drugs on the market target 7TMRs, but only 5% of 
the known 7TMR targets are utilized. Agonists and antagonists of 7TMRs are used in the 
treatment of diseases of every major organ system including the central nervous system, 
cardiovascular, respiratory, metabolic and urogenital systems. The most exploited 7TMR 
drug targets include AT1 angiotensin, adrenergic, dopamine and serotonin (5-
hydroxytryptamine, 5-HT) receptor subtypes (Schoneberg et al., 2004). For instance, 
antagonists of AT1 angiotensin II receptors are used to prevent diabetes mellitus-induced 
renal damage and to treat essential hypertension and congestive heart failure. ǃ-adrenergic 
receptor antagonists, acting on ǃ1- and/or ǃ2-adrenergic receptors, are used in patients with 
congestive heart failure and to treat hypertension and coronary heart disease, while ǃ2-
adrenergic receptor agonists are used in the treatment of asthma, chronic obstructive 
pulmonary disease and to delay preterm labor. Dopamine receptor antagonists, primarily 
acting on D2 receptors, are utilized in the treatment of schizophrenia, while dopamine 
receptor agonists (e.g. precursor for dopamine levodopa (L-dopa)) remain the standard for 
treating Parkinson's disease. Inhibitors of 5-HT uptake, which act as indirect agonists at 
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various subtypes of 5-HT receptors, are used to treat major depressive disorders 
(Schoneberg et al., 2004). 
The increasing importance of dimerization for 7TMRs naturally suggests its possible 
relevance to drug discovery. It seems that the inclination to hetero-dimerize is common 
among the 7TM members and that the tissue-specific expression patterns probably underlay 
the creation of relevant receptor pairs. However, 7TMRs expression has been shown to be 
altered in some pathological situations. In support to the latter preeclampsia was the first 
disorder linked to alteration in the AT1−bradykinin B2 receptor hetero-dimerization 
(AbdAlla et al., 2001). Opioid and dopamine receptor hetero-dimerization has also been 
comprehensively studied, since their putative ligands are used in pathological conditions 
such as basal ganglia disorders, schizophrenia, drug addiction and pain. The increase in the 
dopamine D1-D3 hetero-dimer was shown to be involved in L-dopa-induced dyskinesia in 
patients with Parkinson’s disease and the addition of an adenosine A2A receptor antagonist 
potentiates the anti-parkinsonian effect of L-dopa. Hetero-dimers of glutamate receptors 
mGluR2 and 5-HT2A have been specifically associated with hallucinogenic responses in 
schizophrenia. Furthermore, the opioid ǅ-μ receptor hetero-dimer is a better target than 
either μ or ǅ receptors alone, since blockade of the ǅ receptor decreases tolerance to the 
analgesic effects of the most used μ receptor agonist, morphine (reviewed by (Ferré & 
Franco, 2010; Kenakin & Miller, 2010)). These observations would probably led to broaden 
the therapeutic potential of drug targeting 7TMRs and it is also anticipated that the evolving 
concepts of 7TMR dimerization will be implemented in the BRET-based drug discovery and 
development process (reviewed by (Casado et al, 2009)). 
4. BRET principle and its application in the field of 7TMRs dimerization 
4.1 BRET principle  
BRET is a biophysical method that enables monitoring of physical interactions between two 
proteins fused to BRET donor and acceptor moieties, respectively, dependent on their 
intermolecular distance (10 – 100 Å) and on relative orientation due to the dipole-dipole 
nature of the resonance energy transfer mechanism (Zacharias et al., 2000). BRET is a non-
radiative energy transfer, occurring between a bioluminescent donor that emits light in the 
presence of its corresponding substrate and a complementary fluorescent acceptor, which 
absorbs light at a given wavelength and re-emits light at longer wavelengths. To fulfill the 
condition for energy transfer, the emission spectrum of the donor must overlap with the 
excitation spectrum of the acceptor molecule (Zacharias et al., 2000). BRET occurs naturally 
in some marine species (e.g. in the sea pansy Renilla reniformis) and in 1999, Xu et al. (Xu et 
al., 1999) utilized this approach to study dimerization of the bacterial Kai B clock protein. 
Since then, several versions of BRET assays have been developed that use different 
substrates and/or energy donor/acceptor couples. The original BRET1 technology used the 
pairing of Renilla luciferase (Rluc) as the donor and yellow fluorescent protein (YFP) as the 
acceptor (Xu et al., 1999; Xu et al., 2003). The addition of coelenterazine h, the natural 
substrate of Renilla luciferase (Rluc), leads to a donor emission of blue light (peak at ~480 
nm). When the YFP-tagged acceptor molecule, adapted to this emission wavelength, is in 
close proximity to the Rluc-tagged donor molecule, excitation of YFP occurs by resonance 
energy transfer resulting in an acceptor emission of green light (peak at ~530 nm). The 
substantial overlap in the emission spectra of Rluc and YFP acceptor emission (Stokes shift 
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only ~50 nm) creates a significant problem that has been overcome in a second generation of 
BRET assay (BRET2). In BRET2 assays, Renilla luciferase (Rluc) is used as the donor, the green 
fluorescent protein (GFP) variant GFP2 as the acceptor molecule (excitation ~400 nm, 
emission peak at 510 nm) and the proprietary coelenterazine DeepBlueCTM (also known as 
coelenterazine 400A) as a substrate. In the presence of DeepBlueCTM, Rluc emits light 
peaking at 395 nm, a wavelength that excites GFP2 resulting in the emission of green light at 
510 nm. This modified BRET pair results in a broader Stokes shift of 115 nm, thus enabling 
superior separation of donor and acceptor peaks, as well as efficient filtration of the 
excitation light that it does not come to the detector, thereby enabling detection of the weak 
fluorescence signal. However, the disadvantage of BRET2, compared to BRET1 is the 100-300 
times lower intensity of emitted light and a very fast decay of emitted light (Heding, 2004). 
BRET2 sensitivity can be improved by the development of suitably sensitive instruments 
(Heding, 2004) and the use of Rluc mutants with improved quantum efficiency and/or 
stability (e.g. Rluc8 and Rluc-M) as a donor (De et al., 2007). A third generation BRET assay 
(BRET3) has been developed recently and combines Rluc8 with the mutant red fluorescent 
protein (DsRed2) variant mOrange and the coelenterazine or EnduRen™ as a substrate (De 
et al., 2007). EnduRen™ is a very stable coelenterazine analogue that enables luminescence 
measurement for at least 24 hours after substrate addition and was utilized in the extended 
BRET (eBRET) technology (Pfleger et al., 2006). Therefore, in BRET3, donor spectrum is the 
same as in BRET1, and the red shifted mOrange acceptor signal (emission peak at 564 nm) 
improves spectral resolution to 85 nm, thereby reducing bleedthrough in the acceptor 
window. Improved spectral resolution and increased photon intensity allow imaging of 
protein-protein interactions from intact living cells to small living subjects. Additional 
optimized donor/acceptor BRET couples that combine Rluc/Rluc8 variant with the yellow 
fluorescent protein, the YPet variant and the Renilla green fluorescent protein (RGFP) has 
also been developed (Kamal et al., 2009).  
4.2 BRET and 7TMRs dimerization  
The use of energy-based techniques such as FRET and BRET has been fundamental for 
taking the theme of 7TMRs dimerization/oligomerization at the front of 7TMRs research. In 
2000, BRET was introduced in the 7TMR field demonstrating ǃ2-adrenergic receptor (ǃ2-AR) 
dimerization (Angers et al., 2000) and since then BRET-based information about 7TMRs 
homo-/hetero-dimerization is rapidly accumulating (for a recent reviews see (Achour et al., 
2011; Ayoub & Pfleger, 2010; Ferré et al., 2009; Ferré & Franco, 2010; Gurevich & Gurevich, 
2008a; Gurevich & Gurevich, 2008b; Palczewski, 2010)). As a consequence, knowledge 
databases have been developed to gather and organize these scattered data and provide 
researchers with the comprehensive collection of information about 7TMR oligomerization. 
Existing databases are G protein-coupled receptor oligomer knowledge base (GPCR-OKB) 
(Skrabanek et al., 2007; Khelashvili et al., 2010) that is freely available at http://www.gpcr-
okb.org and G protein-coupled receptor interaction partners database (GRIPDB) (Nemoto et 
al., 2011) available at http://grip.cbrc.jp/GDB/index.html. By analyzing the data in the 
GPCR-OKB, we can see that BRET-based approaches were used more often than other 
experimental approaches such as co-immunoprecipitation, cross-linking, co-expression of 
fragments or modified protomers, use of dimer specific antibodies, fluorescence resonance 
energy transfer (FRET) and time resolved FRET to detect oligomerization in vivo while in in 
vitro systems others methods still prevail (Table 1). The 7TMR pairs for which functional 
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evidence was provided in vivo by BRET are summarized in Table 2. It should be emphasized 
that besides the intra-family hetero-dimers, the members from different 7TMR families also 
form functionally relevant inter-family oligomers (Table 2). 
 
Oligomers (in vivo) 7TMR Family A Family B Family C Family A/C Other 
BRET 18 13 0 1 4 0 
Mus musculus 7 5 0 1 1 0 
Rattus norvegicus 9 5 0 1 3 0 
Homo sapiens 9 8 0 0 1 0 
Other methods 11 7 0 1 2 1 
Oligomers (in vitro)       
BRET 50 40 2 1 6 1 
Other methods 192 160 4 13 13 2 
Table 1. Comparisons of 7TMRs oligomers identified by BRET vs. others methods in 
different 7TMR families in in vivo and in vitro.  Data source GPCR-OKB (http://www.gpcr-
okb.org). 
 
Oligomer name Organism In vivo evidence Potential clinical 
relevance 
Family A 7TMRs    
Adenosine A1 - 
Adenosine A2A 
oligomer (A1 - A2A) 
Rattus norvegicus evidence for physical association in 
native tissue or primary cells 
 
Adenosine A2A - 
Cannabinoid CB1 
oligomer (A2A - CB1) 
Homo sapiens, 
Rattus norvegicus
evidence for physical association in 
native tissue or primary cells, 
identification of a specific functional 
property in native tissue (brain) 
Implicated in 
Parkinson's disease. 
Adenosine A2A - 
Dopamine D2 
oligomer (A2A - D2) 
Homo sapiens, 
Rattus norvegicus
evidence for physical association in 
native tissue or primary cells, 
identification of a specific functional 
property in native tissue (rat 
striatum, human striatum) 
Implicated in 
Parkinson's desease, 
schizophrenia. Level of 
adenosine is increased 
in the striatal 
extracellular fluid in 
Parkinson's disease. 
 
Adrenergic 1B - 
Adrenergic 1D 
receptor oligomer (1B 
- 1D adrenoreceptor)
Homo sapiens, 
Mus musculus 
evidence for physical association in 
native tissue or primary cells, 
identification of a specific functional 
property in native tissue (brain), use 
of knockout animals or RNAi 
technology 
The study 
demonstrated that 
when the 1B-KO and 
1D-KO strains of 
mice are used in 
conjunction with 
antagonists, a different 
pharmacological 
situation emerges 
relative to control 
(sensitivity to 
Phenylephrine). 
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Oligomer name Organism In vivo evidence Potential clinical 
relevance 
Adrenergic 2A 
receptor - Opioid μ 
receptor oligomer 
(2A-adrenoreceptor – 
opioid μ) 
Homo sapiens evidence for physical association in 
native tissue or primary cells 
 
Adrenergic 2 - 
Prostaglandin EP1 
receptor oligomer (2-
adrenoreceptor - EP1) 
Homo sapiens, 
Mus musculus 
evidence for physical association in 
native tissue or primary cells, 
identification of a specific functional 
property in native tissue  (airway 
smooth muscle) 
Implicated in 
decreasing airway 
smooth muscle 
relaxation during 
asthma. 
Cannabinoid CB1 - 
Dopamine D2 
oligomer (CB1 - D2) 
Homo sapiens, 
Rattus norvegicus
identification of a specific functional 
property in native tissue 
 
Chemokine CCR2-
CXCR4 receptor 
oligomer (CCR2 - 
CXCR4) 
Homo sapiens identification of a specific functional 
property in native tissue 
 
Dopamine D1 - 
Histamine H3 receptor 
oligomer (D1 - H3) 
Mus musculus evidence for physical association in 
native tissue or primary cells 
 
Dopamine D1 - Opioid 
μ receptor oligomer 
(D1 – μ) 
Rattus norvegicus evidence for physical association in 
native tissue or primary cells 
 
Dopamine D2 - 
Histamine H3 receptor 
oligomer (D2 - H3) 
Homo sapiens 
Mus musculus 
evidence for physical association in 
native tissue or primary cells 
 
 
Opioid ǅ - Opioid κ 
receptor oligomer (δ – 
κ) 
Mus musculus colocalization in spinal cord tissue-specific agonist 
for pain 
Opioid ǅ - Opioid μ 
receptor oligomer  
(δ – μ) 
Mus musculus evidence for physical association in 
native tissue or primary cells, 
identification of a specific functional 
property in native tissue 
 
Family C 7TMRs    
Ǆ-aminobutiric acid 
GABAb receptor 
oligomer (GABAB1 - 
GABAB2) 
Rattus 
norvegicus, Mus 
musculus 
colocalize in brain GABAB1 agonist 
Baclofen is an 
antispasm drug 
Family A/C 7TMRs    
Adenosine A2A - 
Metabotropic 
glutamate 5 (mGLU 5) 
oligomer   
(A2A - mGLU5) 
Homo sapiens, 
Rattus norvegicus
evidence for physical association in 
native tissue or primary cells 
 
Dopamine D2 - 
Metabotropic 
glutamate 5 (mGLU 5) 
oligomer (D2 - 
mGLU5) 
Rattus norvegicus evidence for physical association in 
native tissue or primary cells 
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Oligomer name Organism In vivo evidence Potential clinical 
relevance 
Adenosine A2A - 
Dopamine D2 - 
Metabotropic 
glutamate 5 (mGLU5) 
oligomer (A2A - D2 - 
mGLU5) 
Rattus 
norvegicus, Mus 
musculus 
evidence for physical association in 
native tissue or primary cells 
 
Serotonin 5-HT2A 
receptor oligomer - 
Metabotropic 
glutamate 2 (5-HT2A – 
mGLU2) 
Homo sapiens evidence for physical association in 
native tissue or primary cells, 
identification of a specific functional 
property in native tissue (brain) 
5-HT2A levels increase 
and mGLU2 levels 
decrease in 
schizophrenia 
 
Table 2. Intra- and inter-family oligomers with in vivo evidence discovered by BRET method. 
Data source GPCR-OKB (http://www.gpcr-okb.org). 
4.3 Interpretation of BRET results – Possible drawbacks 
BRET signal indicates that molecules of the same (or two different) receptors are at maximum 
distance of 100 Å (that equals 10 nm) or more accurately that the donor and acceptor moieties 
are within this distance. The efficiency of energy transfer depends on the relative orientation of 
the donor and acceptor and the distance between them (Zacharias et al., 2000), so that absolute 
distances can not be measured. Experimentally determined Förster distance R0 (distance at 
which the energy transfer efficiency is 50%) for BRET1 and BRET2 is 4.4 nm and 7.5 nm, 
respectively (Dacres et al., 2010). 7TMR transmembrane core spans ~40 Å across the 
intracellular surface (Palczewski et al., 2000), which makes BRET suitable to the study of 
dimerization. However, certain facts need to be considered when interpreting BRET results. 
Firstly, the size of 27 kDa fluorescent proteins and 34 kDa Renilla luciferase is comparable to 
that of the transmembrane core of 7TMRs (diameter ∼40 Å). These proteins are usually 
attached to the receptor C-terminus, which in different 7TMRs varies in length from 25 to 150 
amino acids. Polypeptides of this length in extended conformation can cover 80−480 Å. Thus, 
a BRET signal indicates that the donor and acceptor moieties are at distance less than 10 nm, 
which may occur when receptors form structurally defined dimer or when they are far >500 Å 
apart (reviewed by (Gurevich & Gurevich, 2008a)). The use of acceptor and donor molecules 
genetically fused to 7TMRs can alter the functionality of the receptor; fusion proteins can also 
be expressed in the intracellular compartments, thus making difficult to demonstrate that the 
RET results from a direct interaction of proteins at the cell surface (Ferre & Franco, 2010). The 
use of fusion proteins can therefore be a major limitation for this application. Secondly, 
quantitative BRET measurements are limited by the quality of the signal and noise level. 
Fluorescent proteins and luciferase yield background signals arising from incompletely 
processed proteins inside the cell and high cell autofluorescence in the spectral region used 
(Gurevich & Gurevich, 2008a). Thirdly, so called bystander BRET results from frequent 
encounters between overexpressed receptors and has no physical meaning (Kenworthy & 
Edidin, 1998; Mercier et al., 2002). BRET assays should therefore be able to discriminate 
between genuine dimerization compared to random collision due to over-expression. To 
determine specify of BRET signal the following experiments has been proposed: negative 
control with a non-interacting receptor or protein, BRET saturation and competition assays 
and experiments that observe ligand-promoted changes in BRET (Achour et al., 2011; Ayoub 
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& Pfleger, 2010; Ferre & Franco, 2010). Additionally, interpretation of BRET data also 
requires quantitative analysis of the results, which was so far done only in a small number of 
studies (Ayoub et al., 2002; Mercier et al., 2002; Vrecl et al., 2006). The theoretical background 
of the assays described below provides some guidelines for the appropriate interpretation and 
quantitative evolution of BRET results.  
5. Mathematical models to quantitatively assess the oligomerization state of 
studied receptors 
5.1 Basic assumptions 
Bioluminescent resonance energy transfer takes place at 1-10 nm distances between 
molecules thus allowing study of protein-protein interaction. It is a quite robust tool but still 
some care should be taken with interpretation of the results. Resonance energy transfer is 
described by the Förster equation for energy transfer efficiency E (Förster, 1959): 
 
6
0
6 6
0
R
E
R r
   (1) 
where r is a distance between donor and acceptor, Förster radius R0 depends on spectral 
overlap and dipole orientations yielding R0 values of 4.4 nm for BRET1and 7.5 nm for BRET2 
(Dacres et al., 2010). E is an important parameter in interpretation of the BRET assays used 
for oligomerisation studies. If the BRET luminometer is properly calibrated then E can be 
calculated from the BRETmax signal obtained when all donor molecules are accompanied by 
acceptor molecules: 
 max
max 1
BRET
E
BRET
   (2) 
Calibration should take into account differences in the detector quantum efficiencies at 
donor and acceptor emission wavelengths and the proportion of the detected emission 
spectra of both markers. Knowing a Förster radius for certain type of BRET technology used 
and energy transfer efficiency E we can estimate the distance between the donor and 
acceptor marker species in the protein complex. 
Calculations in presented BRET assays are derived from Veatch and Stryer article (Veatch & 
Stryer, 1977) covering FRET experiments with Gramicidin dimers. In FRET experiments the 28 
Q/Q0 is a measurement parameter representing the ratio between not-transmitted energy Q 
and total energy Q0. Vaecht and Stryer equations have been adopted for BRET experiments 
where we measure the ratio between transmitted T and not-transmitted energy Q: 
 0 1
QT
BRET
Q Q
    (3) 
Single BRET measurements do not give unambiguous proof that receptors form oligomers 
because the signal can be a consequence of random collisions. To get better indication of the 
oligomerisation state several quantitative assays were developed. 
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5.2 BRET dilution assay 
This is a simplest control experiment to check for oligomerisation. Resonant energy transfer 
takes place if the distance between donor and acceptor molecules is in the range of Förster 
radius R0. Molecules can get close enough for BRET also by random collisions (bystander 
BRET) if their density is high enough (Kenworthy & Edidin, 1998; Mercier et al., 2002). 
Excluding random collisions there should be no concentration dependence for coupled 
donor and acceptor molecules. In practice we can approximate the BRET signal as: 
     0BRET BRET k D A    (4) 
where [D] and [A] are donor and acceptor concentrations. With lowering the concentration 
of both receptors simultaneously (dilution) the BRET signal approaches BRET0 which is the 
real oligomerisation signal (Fig. 1). Dilution assay is used to set the concentration range for 
saturation and competition assays (Breit et al., 2004). 
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Fig. 1. BRET dilution assay. Theoretical BRET concentration curves for receptors forming 
monomers or oligomers. A constant ratio between acceptor and donor concentrations 
should be used. 
5.3 BRET saturation assay 
Saturation assay involves expressing a constant amount of donor-tagged receptor with an 
increasing amounts of acceptor-tagged receptor. Theoretically, BRET signal should increase 
with increasing amounts of acceptor until all donor molecules are interacting with acceptor 
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molecules. Therefore, a saturation level is achieved beyond which a further elevation of the 
amount of acceptor does not increase the BRET signal, thereby reaching a maximal BRET 
level (BRETmax) (Achour et al., 2011; Ayoub & Pfleger, 2010; Hamdan et al., 2006; Mercier et 
al., 2002). By using a saturation assay it is possible to obtain the oligomerisation state of 
homologous receptors. BRET saturation curve is derived from Veatch and Stryer model: 
 
 
   2 (1 )
E ADT
BRET
Q DD E AD
     (5) 
where [AD] are acceptor-donor and [DD] donor-donor dimer concentrations. If all receptors 
form dimers and association constants are the same for AA, AD and DD we obtain BRET 
saturation curve for dimers: 
 
 
 
 
 1 (1 )
A
D
A
D
E
BRET
E

 
 (6) 
For higher oligomers a general BRET saturation curve can be derived (Vrecl et al., 2006): 
 
     max
1
1
1 1
N
A
D
BRET
BRET
E E
 
  
 (7) 
where N=1 for dimer, N=2 for trimer and N=3 for tetramer. Theoretical BRET saturation 
curves are presented in Fig. 2. BRET for higher oligomers shows faster saturation. For 
comparison the monomer BRET signal which corresponds to random collisions is presented. 
If receptor concentration is very high then random collisions can generate saturation curve 
similar to that of the dimers. Thus a dilution experiment should be done first to distinguish 
random collisions from the oligomerisation. 
In heterologous saturation assay different receptors are used as donors and acceptors. In this 
case saturation curve is influenced by the affinities for homo-dimer and hetero-dimer 
formation. In practice we can observe a right-shift of the saturation curve where the 
association constant for hetero-dimers is smaller than that of the homo-dimers yielding 
higher BRET50 values. 
5.4 BRET competition assay 
In an attempt to further confirm the existence of oligomer complexes, competition assay can 
be performed. In this assay the concentration of untagged receptor is increased over a 
constant concentrations of donor and acceptor tagged receptors (Achour et al., 2011; Vrecl et 
al., 2006). It is expected that the BRET signal would decrease if untagged receptors compete 
with the tagged receptors for the binding in complexes. Following the Veatch and Stryer 
approach we obtain BRET signal: 
 
 
     2 (1 )
E ADT
BRET
Q DD E AD CD
      (8) 
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Fig. 2. BRET saturation assay. Theoretical curves for oligomer formation are plotted as a 
function of ratio of receptors tagged with acceptor [A] and donor [D] molecules. In the case 
of monomers the BRET signal is created due to random collisions. 
where C represents untagged competitor. If all receptors form dimers and association 
constants are the same for AA, AD, DD, CD, AC and CC dimers we obtain BRET 
competition curve for dimers: 
 
 
 
 
 
 
 1 (1 )
A
D
A C
D D
E
BRET
E

  
 (9) 
Usually in BRET saturation experiments high acceptor to donor concentration ratio is used 
because the variation in this ratio do not influence the BRET signal as much as for 
[A]/[D]=1. In general the interaction with the untagged receptors causes the reduction of 
BRET signal following a hyperbolic curve (Figure 3). We can very well distinguish if the 
oligomerisation is present, but the exact oligomerisation state is difficult to assess. 
Competition assay is more suited for the study of hetero-oligomers where different kind of 
untagged receptor is competing with the homo-oligomers. The saturation curve is shallower 
if there is a low affinity for hetero-dimer formation compared to homo-dimers 
www.intechopen.com
 
Bioluminescence – Recent Advances in Oceanic Measurements and Laboratory Applications 
 
94
0 1 2 3 4 5
0,0
0,2
0,4
0,6
0,8
1,0
1,2
[D]=0.1  [A]=1.0
B
R
E
T
/B
R
E
T
0
[C]
 Heterologous - no interaction
 Dimer - homologous
 Dimer - heterologous
 Trimer - homologous
 
Fig. 3. BRET competition assay. In homologous assay the same receptor is used as a 
competitor, whereas in heterologous assay different receptor is used. For the latter case a 
hetero-dimer with lower association constant than that of the homo-dimer is presented. 
6. Other BRET-based approaches to identify 7TMR hetero-dimerization  
To overcome certain limitations of the classical BRET assays described above, some other 
BRET-based approaches have been developed to study 7TMR oligomerization/ hetero-
dimerization. Sequential-BRET-FRET (SRET) enables identification of oligomers formed by 
three different proteins. In SRET, the oxidation of the RLuc substrate by an RLuc-fusion 
protein triggers the excitation of the acceptor GFP2 by BRET2 and subsequent energy 
transfer to the acceptor YFP by FRET. Combination of bimolecular fluorescence 
complementation (BiFC) and BRET techniques is based on the ability to produce a 
fluorescent complex from non-fluorescent constituents if a protein-protein interaction 
occurs. Two receptors are fused at their C-termini with either N-terminal or C-terminal 
fragments of YFP, respectively, and receptor hetero-dimerization causes YFP reconstitution. 
Then, if there is hetero-trimerization, BRET can be obtained when the cells also co-express 
the third receptor fused to Rluc (reviewed by (Ferré & Franco, 2010)). GPCR-Heteromer 
Identification Technology (GPCR-HIT) utilizes BRET and ligand-dependent recruitment of a 
7TMR-specific interaction partners (such as a ǃ-arrestin, PKC or G-protein) to enable 7TMR 
heteromer discovery and characterization (Mustafa & Pfleger, 2011; See et al., 2011). In this 
set up, only one receptor subtype is fused to Rluc and the second receptor subtype is 
untagged. A third protein capable of interacting specifically with one or both receptors in a 
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ligand-dependent manner is fused to a YFP. Ligand-induced BRET signal indicates that 
activation of untagged receptor or the heteromer results in recruitment of YFP-tagged 
protein to the heteromer. Recently developed complemented donor-acceptor resonance 
energy transfer (CODA-RET) method combines protein complementation with resonance 
energy transfer to study conformational changes in response to activation of a defined G 
protein-coupled receptor heteromer. CODA-RET quantify the BRET between a receptor 
hetero-dimer and a subunit of the heterotrimeric G-protein. It eliminates a contribution from 
homodimeric signaling and enables analyzing the effect of drugs on a defined 7TMR heter-
odimer (Urizar et al., 2011). 
7. Conclusions 
BRET-based techniques are extremely powerful, provided that they are conducted with the 
appropriate controls and correctly interpreted. Quantitative BRET assays allow us to 
support the ability of receptor for homo-dimer and hetero-dimer. Homologous saturation 
assay provide us with the oligomerisation state of receptors. Data interpretation is more 
difficult for hetero-oligomers and the mixtures of monomer, dimer and higher oligomer 
populations. For the quantitative approach we also need to know the relative concentrations 
of all receptors used in the experiment,  which  can  be obtained from radioligand binding, 
Western blot or ELISA assays. 
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